U.S. Capital Wealth Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$286K	Hold	2,750	–	–	0.01%	836
2025 Q4	$284K	Hold	2,750	–	–	0.01%	823
2025 Q3	$248K	Hold	2,750	–	–	0.01%	824
2025 Q2	$242K	Buy	2,750 +150	+6%	+$13K	0.01%	780
2025 Q1	$237K	Buy	+2,600	New	+$234K	0.01%	763

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

U.S. Capital Wealth Advisors's PPH Position: Q1 2026 in Review

U.S. Capital Wealth Advisors held its VanEck Pharmaceutical ETF (PPH) position steady in Q1 2026 at 2,750 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #836.

U.S. Capital Wealth Advisors first reported a position in PPH in Q1 2025 and has held it in 5 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

U.S. Capital Wealth Advisors held 2,750 shares of VanEck Pharmaceutical ETF worth $286K as of Q1 2026.
U.S. Capital Wealth Advisors left its VanEck Pharmaceutical ETF share count unchanged in Q1 2026.
VanEck Pharmaceutical ETF made up 0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #836 holding.
U.S. Capital Wealth Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2025 and has held it in 5 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.